Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals
Roberta Kahn, Kousick Biswas, Anna-Rose Childress, Steve Shoptaw, Paul J Fudala, Liza Gorgon, Ivan Montoya, Joseph Collins, Frances McSherry, Shou-Hua Li, Nora Chiang, Husam Alathari, Donnie Watson, Joseph Liberto, Thomas Beresford, Christopher Stock, Christopher Wallace, Valerie Gruber, Ahmed Elkashef, Roberta Kahn, Kousick Biswas, Anna-Rose Childress, Steve Shoptaw, Paul J Fudala, Liza Gorgon, Ivan Montoya, Joseph Collins, Frances McSherry, Shou-Hua Li, Nora Chiang, Husam Alathari, Donnie Watson, Joseph Liberto, Thomas Beresford, Christopher Stock, Christopher Wallace, Valerie Gruber, Ahmed Elkashef
Abstract
Cocaine dependence is a major public health problem for which there is no FDA-approved pharmacological treatment. Baclofen is a GABA(B) receptor agonist that in preclinical and early pilot clinical trials has shown promise for the treatment of cocaine dependence. The purpose of this multi-site, double-blind study, was to compare the safety and efficacy of baclofen (60 mg/day) vs placebo in an 8-week treatment of individuals with severe cocaine dependence. The primary outcome measure was subjects' self-reported cocaine use substantiated by urine benzoylecgonine (BE). Analysis of the data did not show a significant difference between the groups treated with baclofen and placebo. The current results do not support a role for 60 mg baclofen in treating cocaine dependence in the population studied. The contrast of this result to earlier, preclinical and human pilot data with baclofen may reflect the trial's focus on severe cocaine-dependent users, and/or the need for a higher baclofen dose. Baclofen's potential as a relapse prevention agent was not tested by the current design, but may be a useful target for future studies.
Figures
Source: PubMed